Literature DB >> 10476543

A retrospective review of blood transfusions in cancer patients with anemia.

J T Estrin1, L Schocket, R Kregenow, D H Henry.   

Abstract

BACKGROUND: The factors contributing to blood transfusions in patients with anemia of chronic disease are not well documented in the literature. We analyzed all blood transfusion events within a single oncology practice to determine if certain chemotherapy drugs, cancer types, or other factors necessitated more frequent transfusions. PATIENTS AND METHODS: Out of 331 patients receiving chemotherapy, 103 (31%) patients received a blood transfusion in 1995. Each of these charts was reviewed and sorted by diagnosis, treatment medications, and past transfusion and/or treatment history. Hemoglobin levels were obtained for each transfusion received in 1995.
RESULTS: The average hemoglobin at time of transfusion was 7.9 g/dl. Higher hemoglobin levels at transfusion were observed for patients over the age of 60 and patients who received prior chemotherapy. Lower hemoglobin levels at transfusion were observed for patients receiving Epoetin Alfa and sarcoma patients. The average number of red blood cell (RBC) units transfused in 1995 was 5.1 per patient. More units were given to patients receiving etoposide, while fewer units were given to those receiving ifosfamide. We created a transfusion severity index (TSI) to jointly measure these two variables.
CONCLUSION: The results of this study identify transfusion needs associated with certain groups of cancer patients and with certain types of chemotherapy drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10476543

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  9 in total

1.  The impact of hemoglobin level and transfusion on the outcomes of chemotherapy in gastric cancer patients.

Authors:  Xianren Ye; Jingfu Liu; Yujuan Chen; Na Wang; Rong Lu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 2.  Clinical and economic impact of epoetins in cancer care.

Authors:  Monia Marchetti; Giovanni Barosi
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods.

Authors:  Diego F Ossa; Andrew Briggs; Emma McIntosh; Warren Cowell; Tim Littlewood; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Lifetime Transfusion Burden and Transfusion-Related Iron Overload in Adult Survivors of Solid Malignancies.

Authors:  F J Sherida H Woei-A-Jin; Shu Zhen Zheng; Inci Kiliçsoy; Francisca Hudig; Saskia A C Luelmo; Judith R Kroep; Hildo J Lamb; Susanne Osanto
Journal:  Oncologist       Date:  2019-08-27

5.  An exploration of the influences on clinical decision making and the culture of blood transfusion practise in cancer-related anaemia using an ethnographic methodology.

Authors:  Liz Bishop; Sara Faithfull; Helen Allan
Journal:  Support Care Cancer       Date:  2010-01-26       Impact factor: 3.603

Review 6.  Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.

Authors:  G D Demetri
Journal:  Br J Cancer       Date:  2001-04       Impact factor: 7.640

7.  Use of complementary and alternative medicines among Malaysian cancer patients: A descriptive study.

Authors:  Maryam Farooqui; Mohamed Azmi Hassali; Aishah Knight Abdul Shatar; Muhammad Aslam Farooqui; Fahad Saleem; Noman Ul Haq; Che Noriah Othman
Journal:  J Tradit Complement Med       Date:  2015-03-18

8.  Frequency of allogenic blood transfusion in patients with gastrointestinal cancer: a cross-sectional study in Peru.

Authors:  Jeel Moya-Salazar; Eulogio Cáceres; Jorgelina Blejer; Carlos Gonzalez; Hans Contreras-Pulache
Journal:  Ecancermedicalscience       Date:  2021-09-14

9.  The impact of prolonged storage of red blood cells on cancer survival.

Authors:  Natasha Kekre; Ranjeeta Mallick; David Allan; Alan Tinmouth; Jason Tay
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.